Lifecore Biomedical reaffirmed its 2026 revenue guidance of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million, even as second-quarter revenue fell 6.2% year over year to $34.2 million and net loss widened to $6.2 million. The company expects contractually committed fill-finish demand from its largest customer to double beginning in 2027 and exceed 2026 levels by more than 200% in 2028. Lifecore added six development programs during the quarter, bringing to 11 the number of programs that could commercialize by the end of 2028, and completed a Japanese regulatory inspection without material issues, potentially expanding market access. Management anticipates stronger second-half results driven by higher aseptic and development revenue, and targets full-year free cash flow of roughly $7 million to $10 million.
Lifecore Biomedical Inc.Reaffirms guidance and expects fill-finish demand from largest customer to double in 2027 and exceed 2026 by 200% in 2028.
